CAS No. |
123562-20-9 |
|---|---|
中文名称 |
3-[(1H-咪唑-4-基)甲基]-18-[(1H-吲哚-3-基)甲基]-1-[16-[(1H-吲哚-3-基)甲基]-31-氨基-7-(4-氨基丁基)-39-苄基-4-(2-羧乙基)-10-(羧甲基)-42-(4-羟基苄基)-19,22,28-三(羟甲基)-13-异丁基-45-异丙基-3,6,9,12,15,18,21,24,27,30,38,41,44,47-十四氧代-33,34,49,50-四硫杂-2,5,8,11,14,17,20,23,26,29,37,40,43,46-十四氮杂双环[23.22.4]五十五烷-36-基]-12,15-二(仲丁基)-9-(羧甲基)-6-异丁基-1,4,7,10,13,16-六氧代-2,5,8,11,14,17-六氮杂十九烷-19-酸 |
英文名称 |
3-((1H-imidazol-4-yl)methyl)-18-((1H-indol-3-yl)methyl)-1-(16-((1H-indol-3-yl)methyl)-31-amino-7-(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-42-(4-hydroxybenzyl)-19,22,28-tris(hydroxymethyl)-13-isobutyl-45-isopropyl-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecaazabicyclo[23.22.4]henpentacontan-36-yl)-12,15-di-sec-butyl-9-(carboxymethyl)-6-isobutyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazanonadecan-19-oic acid |
别名 |
ET-2 (HUMAN);ET-2 (HUMAN, PIG, DOG);H-CYS-SER-CYS-SER-SER-TRP-LEU-ASP-LYS-GLU-CYS-VAL-TYR-PHE-CYS-HIS-LEU-ASP-ILE-ILE-TRP-OH;H-CYS-SER-CYS-SER-SER-TRP-LEU-ASP-LYS-GLU-CYS-VAL-TYR-PHE-CYS-HIS-LEU-ASP-ILE-ILE-TRP-OH (DISULFIDE BRIDGE: 1-15 AND 3-11);ENDOTHELIN-II, HUMAN;ENDOTHELIN 2;ENDOTHELIN 2 HUMAN;ENDOTHELIN-2 (HUMAN, CANINE) |
标准英文名 |
3-((1H-imidazol-4-yl)methyl)-18-((1H-indol-3-yl)methyl)-1-(16-((1H-indol-3-yl)methyl)-31-amino-7-(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-42-(4-hydroxybenzyl)-19,22,28-tris(hydroxymethyl)-13-isobutyl-45-isopropyl-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecaazabicyclo[23.22.4]henpentacontan-36-yl)-12,15-di-sec-butyl-9-(carboxymethyl)-6-isobutyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazanonadecan-19-oic acid |
MDL No. |
MFCD00133306 |
分子式 |
C115H160N26O32S4 |
分子量 |
2546.96 |
精确分子量 |
2545.06 |
SMILES |
CCC(C)C(NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC=N1)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC2CSSCC(NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CNC4=CC=CC=C34)NC(=O)C(CO)NC(=O)C(CO)NC2=O)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)N1)C(=O)NC(C(=O)NC(CC1=CNC2=CC=CC=C12)C(=O)O)C(C)CC |
标准SMILES |
CC(CC)C(NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC=N1)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC2CSSCC(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CNC4=CC=CC=C34)NC(=O)C(CO)NC(=O)C(CO)NC2=O)C(=O)NC(C(C)C)C(=O)NC(CC2C=CC(O)=CC=2)C(=O)NC(CC2C=CC=CC=2)C(=O)N1)C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C12)C(O)=O |
用途 |
Endothelin-2 is a potent vasoconstrictor with strong and long-lasting activity (EC50 = 0.52 nM); it acts as a chemoattractant for macrophages and THP-1 monocytic cells (but not for freshly isolated monocytes) via ETB receptor-mediated chemotaxis through the MAPK pathway; it may modulate macrophage behavior in tumor microenvironments, promoting accumulation of activated cells in hypoxic regions; it exhibits pro-inflammatory properties similar to CCL2 and induces biphasic pressor effects in vivo, with an early phase (3–10 min) and a late phase (>10–20 min post-injection) lasting over 1 hour. |
InChIKey |
MLFJHYIHIKEBTQ-UHFFFAOYSA-N |
|
|
评论 |
|---|